Profile data is unavailable for this security.
About the company
CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system. The Company is focused on the development of product candidates and technologies, such as Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers, and Ligand Epitope Antigen Presentation System (LEAPS), with several product candidates under development for the potential treatment of rheumatoid arthritis. Multikine is a biological medicinal immunotherapy comprising a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment before the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikines rationale for use is to incite a locoregional immune response against the tumor.
- Revenue in USD (TTM)0.00
- Net income in USD-29.10m
- Incorporated1983
- Employees43.00
- LocationCEL-SCI CorpSUITE 802, 8229 BOONE BLVD .VIENNA 22182United StatesUSA
- Phone+1 (703) 506-9460
- Fax+1 (703) 506-9471
- Websitehttps://cel-sci.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KALA BIO Inc | 0.00 | -38.96m | 29.63m | 43.00 | -- | 4.32 | -- | -- | -12.47 | -12.47 | 0.00 | 1.49 | 0.00 | -- | -- | 0.00 | -67.64 | -57.83 | -96.17 | -69.32 | -- | 57.06 | -- | -1,553.61 | -- | -11.21 | 0.8367 | -- | -100.00 | -- | 5.85 | -- | -17.31 | -- |
| Opus Genetics Inc | 8.38m | -27.19m | 30.81m | 14.00 | -- | 0.7485 | -- | 3.68 | -1.09 | -1.09 | 0.3369 | 1.31 | 0.1772 | -- | 1.14 | 598,642.90 | -57.50 | -58.31 | -64.30 | -65.94 | -- | -- | -324.45 | -137.92 | -- | -- | 0.00 | -- | -52.20 | -- | -155.83 | -- | -- | -- |
| ImmuCell Corp | 23.84m | -3.81m | 32.08m | 74.00 | -- | 1.20 | -- | 1.35 | -0.4856 | -0.4856 | 3.03 | 2.99 | 0.5357 | 2.35 | 11.43 | 301,746.80 | -8.56 | -5.16 | -9.39 | -5.53 | 26.71 | 40.04 | -15.99 | -12.64 | 1.44 | -6.21 | 0.2922 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
| Tonix Pharmaceuticals Holding Corp | 11.29m | -135.25m | 35.51m | 103.00 | -- | 0.3985 | -- | 3.14 | -52.81 | -52.81 | 0.6477 | 0.4768 | 0.0964 | 0.8291 | 4.05 | 109,621.40 | -115.46 | -59.46 | -134.34 | -65.92 | 20.74 | -- | -1,197.86 | -5,126.73 | 2.78 | -- | 0.0972 | -- | -- | -- | 0.1874 | -- | 320.57 | -- |
| Akari Therapeutics PLC (ADR) | 0.00 | -20.13m | 36.40m | 9.00 | -- | -- | -- | -- | -2.98 | -2.98 | 0.00 | -0.3049 | 0.00 | -- | -- | 0.00 | -307.64 | -149.95 | -- | -435.18 | -- | -- | -- | -- | -- | -378.19 | -- | -- | -- | -- | 43.61 | -- | -- | -- |
| Incannex Healthcare Inc | 86.00k | -23.15m | 36.87m | 9.00 | -- | 5.59 | -- | 428.76 | -1.40 | -1.40 | 0.0052 | 0.3738 | -- | -- | -- | 9,555.56 | -- | -130.12 | -- | -148.24 | -- | -- | -26,922.09 | -3,421.98 | -- | -- | 0.00 | -- | -- | 61.03 | 62.18 | -- | 73.79 | -- |
| Lexaria Bioscience Corp | 411.01k | -4.85m | 38.40m | 5.00 | -- | 3.44 | -- | 93.42 | -0.4455 | -0.4455 | 0.0408 | 0.6403 | 0.0539 | -- | 2.16 | 82,202.00 | -63.85 | -95.67 | -65.93 | -96.58 | 98.83 | 76.98 | -1,185.15 | -1,612.76 | -- | -64.96 | 0.00 | -- | -11.43 | -12.19 | 8.31 | -- | -- | -- |
| CEL-SCI Corp | 0.00 | -29.10m | 38.62m | 43.00 | -- | 4.02 | -- | -- | -0.5806 | -0.5806 | 0.00 | 0.1562 | 0.00 | -- | -- | -- | -100.88 | -70.19 | -124.78 | -78.31 | -- | -- | -- | -15,434.15 | 0.1793 | -36.79 | 0.5517 | -- | -- | -- | 13.99 | -- | 223.59 | -- |
| Verrica Pharmaceuticals Inc | 9.21m | -84.99m | 40.47m | 100.00 | -- | -- | -- | 4.39 | -1.83 | -1.83 | 0.1979 | -0.7467 | 0.1416 | 1.67 | 4.67 | 92,100.00 | -130.68 | -55.75 | -174.03 | -78.33 | 74.08 | -- | -922.81 | -754.94 | 1.22 | -10.16 | 3.82 | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
| Fortress Biotech Inc | 62.50m | -57.53m | 43.27m | 186.00 | -- | 2.05 | -- | 0.6924 | -3.53 | -3.53 | 3.74 | 0.767 | 0.4502 | 2.16 | 6.70 | 336,026.90 | -88.98 | -52.50 | -142.15 | -99.46 | 60.55 | 63.17 | -197.64 | -236.94 | 1.06 | -9.66 | 1.31 | -- | 11.58 | 25.75 | 27.42 | -- | -9.37 | -- |
| United-Guardian, Inc. | 12.31m | 3.48m | 44.61m | 25.00 | 12.80 | 3.92 | 12.44 | 3.62 | 0.7585 | 0.7585 | 2.68 | 2.48 | 0.9684 | 4.74 | 7.44 | 492,490.80 | 27.41 | 29.84 | 31.57 | 34.39 | 53.43 | 55.31 | 28.30 | 28.79 | 6.02 | -- | 0.00 | 97.37 | -14.28 | -4.14 | 0.4616 | -9.92 | 17.19 | -19.73 |
| SCYNEXIS Inc | 8.57m | -36.44m | 44.78m | 29.00 | -- | 0.765 | -- | 5.23 | -0.756 | -0.756 | 0.177 | 1.54 | 0.0692 | -- | 3.61 | 295,379.30 | -29.44 | -30.02 | -35.54 | -36.35 | -71.42 | -- | -425.41 | -86.76 | -- | -- | 0.1843 | -- | 2,652.72 | 252.64 | 206.74 | -- | -- | -- |
| Earth Science Tech Inc | 26.89m | 2.33m | 48.58m | 32.00 | 21.08 | 15.18 | 19.60 | 1.81 | 0.0076 | 0.0076 | 0.0878 | 0.0105 | 6.65 | 23.99 | 201.60 | 840,435.90 | 57.64 | -37.98 | 79.28 | -- | 71.30 | 63.87 | 8.67 | -15.48 | 1.09 | 3.34 | 0.0241 | -- | 24,526.37 | 73.03 | 322.25 | -- | -- | -- |
| BGM Group Ltd | 29.87m | -7.86m | 49.10m | 298.00 | -- | 1.12 | -- | 1.64 | -1.10 | -1.10 | 4.18 | 6.07 | 0.5237 | 3.73 | 25.96 | 100,236.40 | -14.43 | 2.71 | -17.01 | 3.86 | 2.92 | 11.66 | -27.56 | 2.72 | 6.06 | -0.7527 | 0.00 | 26.11 | -28.35 | -1.60 | -822.64 | -- | 12.86 | -- |
Data as of Nov 21 2024. Currency figures normalised to CEL-SCI Corp's reporting currency: US Dollar USD
7.95%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 2.40m | 3.75% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 769.42k | 1.21% |
| Geode Capital Management LLCas of 30 Sep 2024 | 612.86k | 0.96% |
| Osaic Wealth, Inc. (Investment Management)as of 30 Sep 2024 | 308.88k | 0.48% |
| swisspartners AGas of 30 Jun 2024 | 300.00k | 0.47% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 193.51k | 0.30% |
| Thoroughbred Financial Services LLCas of 30 Sep 2024 | 136.76k | 0.21% |
| Osaic Fa, Inc. (Investment Management)as of 30 Sep 2024 | 123.05k | 0.19% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 118.31k | 0.19% |
| Bridgeway Capital Management LLCas of 30 Sep 2024 | 118.30k | 0.19% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
